Abstract
Submission Guideline
  • Submission Guideline
  • Presentation Guideline
  • Grants & Awards
Submission Guideline
Important Dates
  • Abstract Submission Opens
    November 16 (Mon), 2026, 09:00 KST
  • Deadline for Abstract Submission
    December 28 (Mon), 2026, 23:59 KST
  • Notification of Abstract Acceptance
    February 22 (Mon), 2027, 23:59 KST
Online Submission
Official Language
English is the official language for abstract submission, presentation materials, and presentations.
Abstract Submission Guideline
All abstracts must be submitted via the Online System only.
The abstract submitter must choose one topic from the category.
Submitting an abstract does not automatically register you for KCR 2027. Please ensure that all abstract presenters also complete the registration process.
Authors can modify their abstracts before the submission deadline (December 28 (Mon), 2026) on the website.
When you submit your abstract online, your abstract will be automatically edited according to KCR 2027 submission formats.
It is the authors' responsibility to review the submissions and correct them. Submitters are responsible for all typing errors in the abstract.
The submission form is intended for the review of the abstract.
A confirmation letter of abstract submission will be automatically sent to the submitter and corresponding author by e-mail upon the completion of the online submission.
Encore Presentation
An encore presentation is one where you have already presented the submitted work before.
Encore presentations are permitted as long as work has been presented after the last KCR (May 14 (Thu) – 16 (Sat), 2026) when you have presented the work at another academic conference.
Encore presentations are permitted as long as work has not previously been published prior to submission.
Publication in a print or online journal of the abstract in a scientific journal after the submission deadline is not in conflict with presenting it at KCR 2027.
Abstracts published before the abstract review cannot be submitted.
When the abstract is found that it has been published or posted in an online journal before the abstract review, it will be excluded from the review.
Encore submissions must disclose the name and date of the meeting at which they were presented if they are updated or enhanced such as added number or method of analysis, etc. (e.g. "This abstract was presented previously in ACR 2025 conference, at Oct - 2025.").
Use of Generative AI Tools
  • Generative AI tools cannot be listed as an author of an abstract or presentation.
  • If a generative AI tool (such as a large language model, chatbot, or image generator) was used in conducting the study or preparing the abstract, its use must be declared, including the name and version of the tool. The information provided will appear at the end of the abstract.
  • Authors bear full responsibility for the accuracy, integrity, and originality of the entire abstract, including any AI-generated content, and for compliance with patient privacy and data protection standards. All data, conclusions, and claims must be verified by the authors themselves.
  • Tables, figures, and graphs generated using AI must be declared in the submission form and acknowledged in a footnote on oral and poster presentation materials. AI must not be used to generate, alter, or manipulate images that constitute original research results, such as Western blots, X-rays, or photographs.
  • AI declaration details are not counted toward the abstract word limit and are published alongside the abstract as supplementary information, separate from the abstract body, in the abstract book and the online abstract.
  • Non-public data must not be entered into publicly available AI tools.
  • The use of AI must also be clearly stated in oral and poster presentation materials.
  • If a declaration is found to be false or a serious violation is identified, the Academic Affairs Committee may take necessary action following deliberation.
* This policy applies both to AI used in preparing the text of the abstract and to AI used in the research itself.
* KCR 2027 does not use AI detection software to screen submitted abstracts. Review focuses on the integrity and scientific quality of the research, not on whether AI tools were used. Where a concern arises regarding the accuracy of an abstract — for example, references that cannot be verified or inconsistencies between the text and the reported data — the Secretariat may contact the corresponding author for clarification.
Embargo Policy
Communication and/or dissemination of abstracts and information contained therein intended for presentations and/or lectures at the KCR 2027 is prohibited during the embargo period, i.e. starting from the date of acceptance notice until the start of each individual presentation. After the presentation, KCR will allow dissemination and submission to any other third party.
KCR 2027's permission is required prior to dissemination and/or submission to any other third party. In case of any violation of the above-stated policies, KCR 2027, the copyright holder, reserves the right to take appropriate action, including withdrawal of the concerned abstract.
Conflict of Interest Disclosure
If there are relevant financial activities outside the submitted work, the submitter, who is entrusted by all the co-authors, must complete a disclosure form for potential conflict of interest when they submit their abstract. A conflict of interest may exist when an author (or author's institution or employer) has financial or personal relationships or affiliations that could influence (or bias) the author's decisions, work, or abstract. If applicable, the Conflict-of-Interest Disclosure Form can be completed during the abstract submission process.
Guidelines for Submission
Language English Only
Presentation Type
Oral Presentation
Poster Presentation
Title When writing the title, please capitalize the first letter of each word except for articles (a, an, the) and prepositions; i.e., Multi-omics Approach in Rheumatology: From Cells to Precision Medicine.
Format Background/Objective - Methods - Results - Conclusion
Length Title: Up to 30 words
Body: Up to 300 words
Figure & Table Only 1 figure & 1 table is allowed.
* No more than 1 picture, table, graph, or figure should be included in a file.
Keywords Up to 3 keywords
Funding Source (Optional) If you have any funding source to disclose, please state it in ‘Funding Source’ section.
Topic Categories
“Basic Science and Immunology Related to Rheumatic Diseases” is not provided as a separate category. Please submit basic or translational abstracts under the single clinical, disease-based category (1–15) that best matches the main disease focus of your study.
1 Crystal Arthropathies 9 Pediatric Rheumatology
2 Epidemiology & Public Health 10 Rheumatoid Arthritis
3 Miscellaneous Inflammatory Diseases 11 Sjögren's Disease
4 Muscle Biology, Myositis and Myopathies 12 Spondyloarthritis Including Psoriatic Arthritis
5 Orthopedics, Low Back Pain, and Rehabilitation 13 Systemic Lupus Erythematosus and Antiphospholipid Syndrome
6 Osteoarthritis 14 Systemic Sclerosis and Related Disorders Including Raynaud's Phenomenon
7 Osteoporosis and Metabolic Bone Disease 15 Vasculitis Including ANCA-associated and Behcet Disease
8 Pain in Rheumatic Disease Including Fibromyalgia
Abstract Review & Notification of Result
All submitted abstracts will be reviewed by the Academic Affairs Committee according to the review process.
The topic category can be changed after the review by the Academic Affairs Committee.
Authors can submit abstracts for Oral and Poster. However, the final presentation type of the accepted abstract is under the discretion of the Academic Affairs Committee. (Case reports will be presented by Poster Only.)
The acceptance notice of abstracts will be notified via e-mail to the presenting author and corresponding author by no later than February 22 (Mon), 2027.
Awards & Scholarship
Applications for the Travel Grant, Scholarship for Young Rheumatologist/Scientist, and Best Oral/Poster Presentation Awards are submitted together with your abstract. Please review the eligibility requirements on the Grants & Awards page before submitting.
Grants & Awards
Registration for Presenters
The presenting author whose abstract has been accepted needs to register with full payment for the meeting to confirm their participation by the deadline,
March 5 (Fri), 2027.
If the presenting author does not register by the registration deadline, the abstract will be automatically withdrawn from the final program.
If the presenter does not attend the congress or present the abstract without any notification to the KCR 2027 Secretariat in advance, there will be disadvantages in participating in future meetings.
Withdrawal Policy
Abstract withdrawal requests must be made by the presenter themselves.
If you wish to withdraw your abstract, please follow the instructions below:
Before the abstract submission deadline: Log in to My Page and delete your submitted abstract.
After receiving the Acceptance Notice: Log in to My Page and click the “Withdraw Presentation” button to withdraw your abstract.
If the presenter of the accepted abstract does not register by the deadline for presenter registration, March 5 (Fri), 2027, the abstract will be automatically withdrawn from the final program.
Contact for Abstract Submission
KCR 2027 Secretariat  |  Tel. +82-2-6278-8591  |  Email. program@kcr2027.com